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Abstract: COPD is prevalent in Western society and its incidence is rising in the developing 
world. Acute exacerbations of COPD, about 50% of which are unreported, lead to deterioration in 
quality of life and contribute significantly to disease burden. Quality of life deteriorates with time; 
thus, most of the health burden occurs in more severe disease. COPD severity and frequent and 
more severe exacerbations are all related to an increased risk of mortality. Inhaled corticosteroids 
(ICS) have similar effects on quality of life but ICS/long-acting bronchodilator combinations and 
the long-acting antimuscarinic tiotropium all improve health status and exacerbation rates and 
are likely to have an effect on mortality but perhaps only with prolonged use. Erythromycin has 
been shown to decrease the rate of COPD exacerbations. Pulmonary rehabilitation and regular 
physical activity are indicated in all severities of COPD and improve quality of life. Noninvasive 
ventilation is associated with improved quality of life. Long-term oxygen therapy improves 
mortality but only in hypoxic COPD patients. The choice of an inhaler device is a key component 
of COPD therapy and this requires more attention from physicians than perhaps we are aware 
of. Disease management programs, characterized as they are by patient centeredness, improve 
quality of life and decrease hospitalization rates. Most outcomes in COPD can be modified by 
interventions and these are well tolerated and have acceptable safety profiles.
Keywords: COPD, exacerbation, health burden, mortality, inhaled steroids, long-acting 
bronchodilators, long-acting antimuscarinic agents, macrolide, disease management program, 
tolerability, safety, pulmonary rehabilitation, exercise
Introduction
The term, chronic obstructive pulmonary disease (COPD), is of relatively recent origin 
but is related to the terms chronic bronchitis and emphysema that refer to some subsets of 
patients with COPD. These terms have a long history that can be traced as far back as the 
seventeenth and nineteenth centuries, respectively.1,2 Laennec, in his 1837 treatise, gave the 
first clinical description of emphysema.3 The respiratory world had to wait another hundred 
years before a spirometer could be designed to measure time-dependent expiratory 
volumes4 and allow the physiology of airflow obstruction to be studied. Two phenotypes 
of COPD emerged, the so-called ‘American Emphysema’ and ‘British Bronchitis.’ Both 
Fletcher and Burrows showed similarities between these two conditions,5,6 which were 
later shown to have similar mortality.7 It is worth noting that at this stage the definition 
of COPD was clinicoradiological.7 William Briscoe is believed to be the first person to 
use the term COPD in discussions at the 9th Aspen Conference8 and Sukumalchantra and 
Williams were one of the first groups of authors to publish data using the term COPD.9 
Following these earlier works, the anatomic location of the primary lesion in COPD International Journal of COPD 2009:4 204
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was shown to be the small airway and the basis of COPD 
pathology was suggested to be inflammation.10–12 In 1995 both 
the American Thoracic Society and the European Respiratory 
Society published for the first time standards for the diagnosis 
of COPD.13,14 These standards established the spirometric basis 
for the definition of COPD.
COPD is now defined by airflow obstruction, which 
may be associated with chronic bronchitis, bronchiolitis, or 
emphysema.13 Other synonyms that have historically been 
associated with COPD include chronic obstructive bronchitis, 
chronic airflow limitation, chronic airflow obstruction, chronic 
airways obstruction, nonreversible obstructive airways disease, 
chronic obstructive airways disease, chronic obstructive lung 
disease, and some cases of chronic asthma.15
The major manifestation of airflow obstruction in COPD 
is reduced maximum forced expiratory flow in 1 second 
(FEV1) and slow forced emptying of the lungs (forced vital 
capacity, FVC) such that the ratio of FEV1 to FVC is less 
than 70%. Another characteristic is that these physiologic 
features do not change markedly over months.14 However, 
the natural history of this disease is that most of the lung 
function impairment is progressive.14 Importantly, airway 
hyperactivity and partial reversibility may also be features 
of COPD provided that at maximal reversibility, the ratio of 
FEV1 to FVC is still less than 70%.16
The severity of COPD is classified in terms of FEV1 
because FEV1 is reproducible and is considered the most 
significant predictor of prognosis in COPD as supported by 
a wide range of studies over time,17–22 Since FEV1 depends 
on gender, age, and height, the derived variable FEV1% 
predicted (FEV1%) is used. FEV1% is the ratio of postbron-
chodilator FEV1 to FEV1 predicted for age and height as 
determined from epidemiological studies.16
In this review we will look at the prevalence and 
importance of COPD as a common chronic disease: there 
is evidence that even from an optimistic view point the 
prevalence of COPD will rise markedly within the next 20 
years. Most of the health burden in COPD arises from phar-
macologic intervention whether as in- or outpatients. This is 
more marked in the later stages of COPD when exacerbations 
are more frequent. Thus COPD exacerbation has emerged 
as an important outcome measure in COPD. There are, 
however, several methodological issues with the concept of 
an exacerbation from event definition to counting of COPD 
exacerbations during interventional studies. The relationships 
of exacerbation to health status and difficulty in modifying 
physiological measures in COPD have brought health status 
into focus as an important outcome measure. However the 
final outcome measure for any intervention is mortality. 
We may well have treatments that reduce mortality. After 
a review of each of these concepts we look at how various 
interventions both pharmacologic and nonpharmacologic 
modify these interventions. No intervention will be effec-
tive unless it is patient friendly and so we also consider 
patient-focused perspectives on treatment. We will not 
consider newer drugs where studies have yet to show effects 
on exacerbations, quality of life and mortality.
The prevalence of COPD
Several studies have examined the prevalence of COPD 
both in the developed and developing world and concur 
on the importance of this condition,23–33 In 1990, the total 
deaths from COPD were estimated at 2.2 million and it 
was ranked the sixth leading cause of death.25 Even by 
conservative estimates it is thought that the worldwide 
number of deaths in 2020 will be 3.5 million and COPD 
will be ranked third amongst the leading causes of death.25 
During 2000, an estimated 10 million US adults reported 
physician-diagnosed COPD and in the USA alone, COPD 
was responsible for 8 million physician office and hospital 
outpatient visits, 1.5 million emergency department visits, 
726,000 hospitalizations, and 119,000 deaths.34 The greatest 
risk factor for disease development in the developed world 
is tobacco smoke; however in the developing world biomass 
fuels have been implicated particularly in women.35
Worldwide, COPD affects 9.8% of men and 5.6% of 
women.36 However a turn-of-the-century report from the UK 
indicated that the prevalence rates of COPD appear to have 
peaked in UK men but are continuing to rise in women.37 
This reverse in the gender trend in COPD prevalence in 
the developed world has been confirmed by reports from 
Austria that have found equal prevalence in both genders 
for COPD as well as tobacco use.38 Thus the prevalence of 
COPD in women can be expected to rise worldwide over 
the next decade.39,40
Exacerbation rates
The importance of COPD exacerbations to the natural history 
of COPD and disease burden has only been recognized within 
the past 10 years. In 1975, Tager and Speizer suggested that 
“once obstructive disease becomes manifest as abnormal 
FEV1, intercurrent illnesses [exacerbations] have little effect 
on rates of FEV1 decline” and disease severity and thus the 
“current concern over rational use of antibiotics…and the 
economic burden that unnecessary use may represent…
[requires] reassessment.”41 Our current conceptualization of International Journal of COPD 2009:4 205
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COPD exacerbations has carried us well beyond the almost 
negligible concern expressed in the above statements.
Table 1 shows 9 studies of at least 1 year’s duration in COPD 
patients conducted within the past 40 years. Many factors 
affect the ability of such studies to draw definitive conclusions 
about COPD exacerbations and make it difficult to compare 
studies. One major factor is the heterogeneous nature of 
COPD.42 This factor is further accentuated because 3 of the 
studies17,43,44 included unselected subjects whereas the other 
studies included only patients with COPD. Another variable 
is the method used to detect COPD exacerbation. Relying on 
the ability of patients to recall exacerbations17,45 may not be 
as accurate as active surveillance.43,46,47 Other confounding 
variables may include geography (eg, weather, climate, air 
pollution), genetic makeup of the population under study and 
frequency of follow-up. Data from the London COPD cohort 
suggest that in a single center study using a selected group of 
COPD patients, active surveillance may be the most important 
factor in detecting COPD exacerbations.46
The annual rate of COPD exacerbations has been 
estimated from several different studies to be as low as 0.5 to 
a high of 3.5 exacerbations per patient.46,48,49 Hospitalization 
rates have depended on type of study but range from as low 
as 0.09 to 2.4 per patient per year.49 Thus, from this brief 
survey it would appear that the more closely patients are 
followed up in studies the higher the detection rate for COPD 
exacerbations. However as far as we are aware, no long term 
study has found a mean exacerbation rate of greater than 
about 3 exacerbations/year and so this number may represent 
an upper limit to the mean rate in all populations and is of 
significance for interventional studies.
Methodologic issues in exacerbation 
detection and type of exacerbation
Frequency of monitoring
Of the studies mentioned in Table 1, the study of Kanner 
et al44 is the only long-term study of exacerbations with 
a low detection rate despite close follow up with weekly 
telephone calls and 3-monthly clinics, but this may have 
been related to the inclusion of patients without COPD. 
Their findings are at variance with both the London COPD 
Study and the INSPIRE Study,46,47 both of which used diary 
cards to detect exacerbations, and Monto et al who also 
monitored their patients by weekly telephone calls.43
Event definition
Both Monto and Kanner used a similar definition of exacerbations 
consisting of increase in or new onset of cough, wheeze 
and sputum changes but Monto et al also included ‘painful 
respirations.’ On the other hand the London COPD Study and 
Anthonisen used a slightly more restrictive definition requiring 
at least one or more of an increase in or new onset of dyspnea, 
sputum purulence or sputum volume or one of these and any one 
of a cold, wheeze, cough, sore throat or fever.45,46 Anthonisen’s 
lower detection rate compared to the Monto, The London 
COPD and INSPIRE studies may have been related to his 
use of patient recall at the 3-monthly follow-up visits. Despite 
the heterogeneity in the definition of COPD exacerbation these 
studies all have one feature in common, which is that they used 
symptom-based definitions of an exacerbation of COPD.
Since the publication of the ISOLDE Study,50 which used 
a treatment-based definition of exacerbation and the initial 
results of the London COPD Study, which like Anthonisen, 
Table 1 Comparison of 9 studies of exacerbations over 30 years
Author/Year Country N Years Patient type Exac. freq Follow up
Monto43 USA 142 1 COPD and 2.33 Telephone
NOCBa weekly
Fletcher17 england 792 8 Unselectedb 2.34 6 monthly
Kanner44 USA 84 4 Mixedc 0.34 Telephone
weekly
Anthonisen45 Canada 173 3.5 COPD 1.30 3 monthly
Seemungal48 UK 70 1.0 COPD 3.00 Diary cards
Seemungal46 UK 101 2.5 COPD 2.50 Diary cards
TOrCH104 world wide 6112 3 COPD 1.13c 3 monthly
INSPIre51 europe 1323 2 COPD 1.30d Diary cards
UPLIFT136 world wide 5993 4 COPD 0.85c 3 monthly
Notes: aNOCB, Nonobstructed chronic bronchitis; bIncluded normal subjects; cMixed, COPD and other airway diseases; cPlacebo group only; dMean value for both arms using 
the health care utilization definition. Using the symptom-based definition the mean number of exacerbations was approximately 3.00.International Journal of COPD 2009:4 206
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did not, there has been debate about the true incidence of 
COPD exacerbations. This question has now been answered 
by the INSPIRE Study which is the first long-term study 
of COPD exacerbations to compare the two types of 
exacerbations using the so-called symptom-based definition 
as well as the treatment-based definition.47,51 The results of 
the INSPIRE study show that if a symptom-based definition 
is used exclusively then the exacerbation rate detected is 
3 per year but if a treatment-based definition is used then 
the rate detected is approximately 50% of this or about 1.5 
exacerbations per year. Thus about 50% of symptom-defined 
COPD exacerbations are not treated by physicians and this 
may represent a different type of exacerbation.
Unreported exacerbations
The above observations lead logically to the hypothesis that 
about 50% of exacerbations are untreated, or at least not 
reported to physicians. This feature of COPD exacerbations 
was first detected by the London COPD Study.48 Initial reports 
from the London COPD cohort suggested that the size of this 
reporting gap is about 50% but later reports suggested that 
it may be as high as 67%52 which is consistent with reports 
from a Canadian cohort.53 In a study of 625 exacerbations 
Wilkinson et al showed that patients with a higher reporting 
rate had a better quality of life.52 Langsetmo et al in a 6-month 
study of 421 patients with 501 exacerbations have shown that 
several factors appear to predict the tendency not to report 
exacerbations and these include older age and more severe 
disease.53 Further, a small number of symptoms at onset 
and weekends were associated with a tendency not to report 
exacerbations53 or report later.52 These results are supported 
by those of Vijayasaratha et al who reported on COPD 
exacerbations in a small number of COPD patients with 
alpha-1-antitrypsin deficiency and showed that the unreported 
exacerbations also had fewer symptoms at onset.54
reported exacerbations
Exacerbations receive the attention of the physician either in 
general practice or at hospital. COPD carries a greater burden 
than asthma with respect to general practice consultations 
and the consultation rate increases with age.55 Data from 
The Lung Health Study showed that unscheduled general 
practice consultations may be a valid though indirect measure 
of exacerbation rates and that this parameter is responsive 
to therapy.56
A survey of medical admissions found that 7.3% of 
male and 3.2% of female admissions aged between 56 
and 74 years had COPD.57 The number of COPD hospital 
admissions in a typical UK health district of 250,000 
population is about 50% greater than for asthma.57 Similarly 
in the USA about 50% of discharges classified as chronic 
airflow disease including asthma (ICD codes 490–496) were 
due to bronchitis (chronic or unqualified) corresponding 
to ICD9 codes 490 and 491.34 Also in the UK, inpatient 
hospital stay exceeds that for asthma by a factor of 500%. 
Thus COPD carries a significantly greater hospital burden 
than asthma.
relationships to exacerbation
Factors associated
Three of the studies quoted in Table 1 attempted to determine 
factors associated with frequent exacerbations. One of the 
first long term studies of COPD exacerbations was that of 
Fletcher et al who studied ‘chest episode’ frequency in a 
cohort of male postal workers over 10 years. These chest 
episodes were never rigorously defined by the authors but 
Fletcher found associations with migraine, hay fever and a 
history of childhood bronchitis which, apart from migraine, 
all became nonsignificant when age, phlegm score and airway 
obstruction were taken into account.17 Fletcher concluded 
that “chronic mucus hypersecretion is a major cause of chest 
episodes” which is also supported by the Copenhagen City 
Heart Study.58 Over the past 10 years several studies have 
found factors associated with the rate of COPD exacerba-
tions and these include mucus hypersecretion,48,59 lower 
airway bacterial colonization,60 airway inflammation61 and 
frequency of virus infection.62 Exacerbations of COPD lead 
to a deterioration in the quality of life of COPD patients 
and contribute significantly to disease burden,48,50,63 greater 
severity of COPD44,64,65 and mortality.66
Prior treatment
One of the first studies to show that withdrawl of inhaled 
steroids was associated with the occurrence of exacerbations 
was the Isolde study.67 This has been found in other studies 
since then but Suissa et al have reanalyzed data from the 
OPTIMAL Study according to whether patients were initially 
ICS-exposed or ICS-naive.68 They found that patients with 
prior ICS treatment who are switched to bronchodilator during 
randomization are more likely to exacerbate compared to those 
remaining on ICS. But importantly, they found no difference 
between treatments in the ICS-naive patients. Thus regardless of 
definition used, the prior medication history of the patients may 
be important when exacerbation rates are an outcome measure 
in COPD studies. This has not been taken into account during 
analysis of exacerbations in any study of COPD so far.68International Journal of COPD 2009:4 207
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Statistical issues
Most of the interventional studies referred to later on used 
the health care utilization definition of an exacerbation when 
counting exacerbations as an outcome measure. However, 
statistical modeling of exacerbation rates has turned out to 
be rather complex. Cohort studies have shown evidence for 
a phenotypic frequent exacerbator.48,60 While the occurrence 
of exacerbations within individual patients may follow a 
Poisson distribution, exacerbations between patients may not. 
One suggestion that such exacerbations may follow a gamma 
distribution has been debated.69,70 Where differences between 
treatment arms are large such theoretical issues may not be 
of importance but when differences are small the choice of 
statistical model will determine the importance of the result.
Health status and health burden
Measurement of health status in COPD has become more 
frequent since the work of Jones and colleagues71 and it is a 
European requirement that all clinical trials of new drugs for 
COPD should incorporate a symptomatic measure, such as a 
health status questionnaire, as a coprimary endpoint.72
Quality of life as a concept
The concept of quality of life is a difficult one to measure; 
it may be defined as the gap between that which is desired 
and that which is achievable.71 Because of the difficulty of 
measurement of this parameter and the fact that we in the 
health services are concerned with more specific targets, 
clinicians have sought a more restrictive term, health-related 
quality of life (HRQoL), which is the subjective experience 
of health on quality of life.
Studies of HRQoL in COPD over a wide range of 
severity have consistently shown that patients with COPD 
have significant decrements in their HRQoL.73,74 In COPD 
patients, quality of life scores have been used in the 
assessment of effects of medication,75 depression,76 oxygen 
therapy,73 intermittent positive pressure ventilation,77–79 
pulmonary rehabilitation,80–82 hospital readmission83 and 
exacerbations.48,84
Health-related quality of life questionnaires
Questionnaires used for assessment of quality of life may 
be categorized as generic or disease-specific. Generic 
questionnaires were designed to make standardized comparative 
assessments between populations of patients. However most 
questionnaires of this type (for example the Sickness Impact 
Profile, Short Form 36) may be rather insensitive to changes 
in health.75 Disease-specific questionnaires include the 
Chronic Respiratory Questionnaire (CRQ)85 and St. George’s 
Respiratory Questionnaire (SGRQ).86
The CRQ attempts to overcome the problem of generic 
questionnaires by customizing the questionnaire to the 
individual patient and patients are encouraged to compare 
their current state of health with their previous reports. 
A self-reported version of the questionnaire exists87 and the 
minimal clinically important difference between scores using 
this questionnaire has been reported as 0.5.88
The advantage of the SGRQ86 is that it has standardized 
instructions, which require the same response. There is no 
evidence that by so doing the SGRQ is less sensitive than 
other questionnaires to different levels of health.75 However 
as a standardized questionnaire, the SGRQ has the advantage 
of allowing direct comparison between different patient 
populations and treatment groups and has been shown to be 
responsive when used for these comparisons.71,89 Because 
of this standardization further analysis of the disturbances 
to life that occur in airways disease are possible. The 
SGRQ is scored from 0 (good) to 100 (poor) through a 
total score. However the SGRQ examines disturbances to 
quality of life by the symptoms component of the score, 
which assesses the degree of distress due to frequency and 
severity of respiratory symptoms, the impacts component, 
which addresses psychosocial effects and the activities 
score, which assesses effect on daily activities.86 The 
SGRQ measures changes in health status and it has been 
shown that a clinically significant difference is equivalent 
to a 4-unit change in the SGRQ score.90 The importance of 
the SGRQ in COPD has been further supported by recent 
studies showing relationships with systemic biochemical 
parameters.91–93
Disability and COPD
Disability adjusted life years (DALYs) is a measure of health 
burden that consists of the sum of years of living lost (YLLs) 
and years of living with disability (YLDs).25 In 2001 smoking 
was projected as the major risk factor for 4 million deaths 
and contributed about 5% of DALYs worldwide.94 Deaths 
due to smoking are expected to rise to about 8.4 million by 
2020.25 By 2020 COPD will be expected to contribute about 
4.1% of total DALYs worldwide. One study in Brazil has 
estimated that COPD accounts for 32% of all DALYs95 and 
this is consistent with trends already predicted by Murray 
that increases in DALYs for COPD will be greater in the 
developing world.25,96 Interventions, which decrease mortality 
in COPD, will decrease YLLs but there will also be an 
increase in YLDs. Since no currently known intervention is International Journal of COPD 2009:4 208
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associated with cure in COPD, DALYs may not be a suitable 
outcome measure at present in COPD.
economic burden of COPD
Data from the Office of National Statistics in the United Kingdom 
showed that there were 203,193 hospital admissions for COPD 
in 1994.97 The average length of inpatient stay was 9.9 days. 
The National Health Service Executive published data in 1996 
showing that the medical cost of COPD in the United Kingdom 
was £846 million or £1,154 per person per year.98 The bulk 
of this cost was due to pharmaceutical treatment.99 Similar 
data from the United States showed that 72.8 % of yearly 
expenditure of US$14.7 billion was due to hospitalization and 
that approximately 50% of the total Medicare payments for 
those with COPD were incurred by approximately 10% of the 
Medicare beneficiaries (Division of Epidemiology, NHLBI).
A US study of per patient direct costs (in $US 2005), 
using recent data yielded attributable cost estimates (costs 
deemed to be related to COPD) in the range of $2,700 to 
$5,900/patient annually, and excess cost estimates (total 
costs incurred by COPD patients minus total costs incurred 
by non-COPD patients) in the range of $6,100 to $6,600 
annually.100 Most of the health burden from COPD comes 
from hospital visits in late disease.34 In a study of health 
insurance claims over the period 1999 through 2002, 
Nurmagambetov et al found that the number of hospital 
admissions and length of stay in hospitals decreased while 
the number of outpatient visits increased over this period. 
During this period the estimated COPD-related total medical 
costs per patient decreased 22% largely because of a decrease 
in the cost of hospitalizations for COPD, thus showing that 
COPD costs can be effectively reduced through decreasing 
hospitalization101 and these changes have been related to 
quality of life scores.102 These data suggest that hospital 
admission rates are a suitable measure of health burden in 
COPD and respond to interventions.
Mortality
Mortality rates in COPD
There is substantial variability among and even within countries 
and between sexes in COPD mortality.103 For example, deaths 
from COPD are greater in Scotland than the rest of the UK. 
Though cold temperatures may be a factor in this, it is not entirely 
clear that this is in fact so, as the death rates from COPD in 
Canada do not exceed those of the USA, and COPD death rates 
in Norway are not particularly high (28 per 100,000 males).103 
Death rates are lower among women than men in all countries. 
Surveys of deaths in the US show a substantial increase in death 
rates from COPD between 1985 and 1995, consistent with an 
increasing time trend in reporting of COPD.103
Mortality and lung function
In a multicenter prospective study of positive pressure 
breathing over 33 months, Anthonisen et al found a mortality 
rate of 23% and showed that mortality in COPD was related 
to postbronchodilator FEV1 and response to bronchodilators.18 
This study involved 985 patients with a mean FEV1 of 36% 
predicted. When patients were stratified by FEV1, patients 
in the strata with FEV1 less than 40% predicted had greater 
mortality even with adjustment for age. Mortality in the group 
with a FEV1  50% predicted was only slightly different from 
that of the group of healthy smokers. The results of this study 
are strongly supported by the MIDSPAN study, conducted 
in the general population in Renfew and Paisley in Scotland 
starting in 1972 through 1976 and following mortality over 
15 years.21 The Scottish study was based on 4439 deaths and 
the study showed that low FEV1 was related to deaths from 
all causes but also vascular disease and lung cancer.21 Further 
support for the relationship of FEV1 to prognosis in COPD 
comes from the atherosclerosis risk in communities study in 
which Mannino et al showed that survival in COPD patients 
is related to GOLD stage.16
Taken together, these studies suggest that impaired lung 
function is related to mortality in the general population. 
They also show that in the COPD population FEV1 below 
50% of predicted is strongly related to mortality. Thus inter-
ventions at this stage of COPD or earlier may be particularly 
effective.
Mortality and COPD exacerbations
Using a service-based definition of COPD exacerbation 
defined by need for emergency department treatment, 
SolerCataluña and colleagues were able to show for the first 
time that exacerbation frequency influenced mortality.66 This 
was a study of 304 men with COPD in Spain over 5 years. 
The study showed that patients with 3 or more exacerbations 
had a survival rate of 30% at 5 years whereas those without 
exacerbation had a survival rate of 80%. Survival rate was 
also influenced by need for readmission, those requiring 
readmission having a 20% survival at 5 years.66
In-hospital mortality varies between less than 10% and 
60%, based on the severity level of the population studied.49 
Mannino et al analyzed data from the Atherosclerosis Risk in 
Communities (ARIC) study and found that the overall rate of 
death varied from 5.4 per 1000 person years among normal 
subjects to 42.9 among subjects with GOLD Stage 3 or 4 COPD. International Journal of COPD 2009:4 209
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Death rates from COPD depend on degree of severity, the 
highest death rate from COPD occurring in severe COPD.16
Causes of death in COPD
Vascular diseases and lung cancer appear to be major 
causes of death but more so in the severe COPD category.16 
SolerCataluña showed that respiratory causes accounted for 
67% of deaths in their cohort.66 The TORCH Study was the 
first interventional study in COPD with mortality as a primary 
outcome measure.104 The study was a randomized double blind 
trial with 4 treatment arms: placebo, salmeterol, fluticasone 
and salmeterol/fluticasone (SFC). The study recruited 6112 
patients in 444 centers in 42 countries and the mortality rate 
in the 3-year study period was 875 subjects. The study was 
well designed to study mortality and had an independent 
adjudication committee for causes of deaths, thus eliminating 
between-country variations in death certification. Unlike the 
SolerCataluña study,66 the TORCH study found an almost 
equal contribution of respiratory (35%) and cardiovascular 
causes (27%) of deaths in COPD. However the death rates 
between the two studies were different, the TORCH study 
having an average annual death rate of 4.7%, about 50% of 
that of the SolerCataluña study.66 Thus these two studies may 
have been describing the same events but in two different 
types of COPD subjects.
Interventions
Inhaled corticosteroids (ICS)
The first long-term randomized controlled trial (RCT) of ICS 
to show a significant effect in COPD was the ISOLDE study 
of 751 UK subjects with FEV1  85%. The rationale for the 
ISOLDE study was based on 3 previous studies all having 
positive effects on FEV1 decline. One, a large, retrospective, 
open-label study, involved oral corticosteroids;105 another 
study was conducted in a combined pool of asthma and 
COPD patients;106,107 and finally, meta-analyses of ICS 
including (beclomethasone users).108 Though the ISOLDE 
study aimed for all severities of COPD, the mean FEV1 at 
recruitment was in fact 50% (SD 14.7%). This was the first 
prospective study to find an effect of ICS on any outcome 
measure in COPD. The study found no difference in the 
primary endpoint that was the annual decline in FEV1 in 
common with previous studies of budesonide.58,109 However 
the ISOLDE study found a 25% reduction in exacerbation 
rates in the fluticasone (500 µg BD) arm compared to the 
placebo arm.50 Fluticasone propionate significantly reduced 
the rate of decline in quality of life, delaying the average 
time for a clinically important reduction in health status 
from 15 to 24 months compared to placebo. This was a 
landmark study in COPD therapeutics as it showed for the 
first time that health status declines at a measurable rate 
of 3.2 unit/year (in the placebo arm) and further that this 
outcome may be modified.63,110 From then on health status 
and exacerbation rates became accepted outcome measures 
in most interventional studies in COPD.
The earlier long term studies of Vestbo58 and Pauwels109 
either found no effect on, or did not look at, health status or 
exacerbations. In the Vestbo study, though exacerbations were 
an outcome measure, there appears to be no precise definition 
unlike the ISOLDE study where exacerbations were defined 
by need for treatment. Further, in both the Vestbo and Pauwels 
studies the patient population was mild COPD (mean FEV1 
87% and 77% predicted, respectively) compared to ISOLDE: 
50%. The results of the ISOLDE study were supported by 
the shorter (1 year) TRISTAN study,111 which showed a 19% 
reduction in exacerbation rates but no significant difference in 
hospitalization or quality of life scores for fluticasone relative 
to placebo. Hence the GOLD guidelines (2004) suggest that 
ICS be used in COPD for severe disease with FEV1  50% 
or where there are frequent exacerbations.
Following the essentially negative Vestbo and Pauwels 
studies two further studies of budesonide in more severe 
COPD patients (FEV1 36%) over 1 year with primary outcome 
measure as the rate of oral steroid-treated exacerbations, also 
found no effect for the ICS on exacerbation rate112,113 and only 
one study found improved quality of life in the ICS arm.113 
It is likely that the difference between outcomes in the two 
studies was due to the differing designs. Medications were 
withdrawn prior to recruitment in the Szafranski study112 but 
patients in the Calverley study113 were optimized with oral 
steroid therapy prior to randomization as was done in the 
ISOLDE Study. Though the primary outcome measure of 
both the Calverley and Szafranski studies was exacerbation 
rate, it is interesting that both studies found only a trend 
toward a reduced exacerbation rate in the budesonide arm. 
Thus it is likely that they were underpowered to detect a 
difference in effects of ICS and had they been conducted 
over a longer period (eg, the ISOLDE Study, 3 years) the 
results might have been different. However we cannot draw 
definitive conclusions on relative efficacy of these ICS in 
COPD from these studies as there have been no ‘head to 
head’ comparisons between fluticasone and budsonide
Long-acting β2- agonists (LABAs)
The latest GOLD guidelines recommend use of a long-acting 
inhaled beta-adrenergic receptor agonist (β2-agonist) for International Journal of COPD 2009:4 210
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maintenance treatment of COPD.114 Several studies of 
LABAs have looked at exacerbations as outcome measures. 
In a 4-month, randomized, placebo-controlled study of 
670 COPD patients, Boyd et al found no difference in 
exacerbation with salmeterol; however in a similar study 
which also included an ipratropium arm Mahler et al found 
similar exacerbation rates in all arms but significantly 
prolonged time to the first exacerbation for salmeterol 
compared to placebo (p = 0.005) as well as ipratropium 
(p = 0.0411).115,116 By the end of the study, 17% of the 
patients in the salmeterol arm had at least one exacerbation 
as compared to 27% and 31% in the ipratropium and placebo 
arms, respectively.116 Dahl et al conducted a placebo-
controlled comparative study of formoterol (2 dose strengths: 
12 and 24 µg/day), ipratropium and placebo in 780 patients 
with moderate to severe COPD over 3 months.117 They found 
no difference in exacerbations requiring treatment but there 
was a significant decrease in mild exacerbations (ie, those 
requiring reliever use only) between the formoterol arms and 
the placebo arm. Larger studies all showed significant falls 
in exacerbation rates in the salmeterol arm of 20%111 and 
15%104 but not formoterol112,113 though there was a significant 
difference in mild exacerbations requiring just reliever use 
in the latter two studies.
The first study to describe a significant effect of a 
LABA on quality of life in COPD was the 4-month placebo-
controlled study of salmeterol in 283 COPD patients. The 
study showed a highly significant improvement in the 
salmeterol arm of the study.75 This was supported by another 
study which used the CRQ to measure quality of life116 and 
a later study using formoterol.117 However, the subsequent 
3-month study of Rennard et al found only a nonsignificant 
trend toward better quality of life in the salmeterol arm 
compared to placebo.118
The early studies found no difference in mortality 
between LABA and placebo, arguably because of their short 
durations. Based on many of these small studies, a meta-
analysis of 22 trials concluded that β2
-agonists are associated 
with an increased risk of respiratory deaths.119 However this 
meta-analysis included only seven studies of salmeterol, 
all of duration 3 to 6 months and even less (five studies) 
of formoterol of duration 3 to 12 months.119 None of these 
12 studies was individually powered to detect differences in 
death rates. In contrast, a prospective study of 416 patients 
in five Nordic countries detected an association between 
treatment with LABAs and decreased death rates following 
discharge from hospital.120 The only study of COPD patients 
that was powered to detect a difference in death rates between 
interventional and placebo arms was the TORCH study. This 
study showed no statistically significant difference between 
placebo and salmeterol in death rates but the two survival 
curves diverged within the first year and the final hazard 
ratio was compatible with a trend toward improved survival 
in the salmeterol arm (adjusted hazard ratio: 0.879 [95% CI 
0.729–1.061]), compared to placebo.
There are now data that the LABA, salmeterol, may 
improve survival in COPD. According to Suissa et al, the 
TORCH study may be analyzed as a 2 × 2 factorial trial 
(ie, LABA, ICS, both, neither).70 Results by this analysis 
show that salmeterol is associated with a 17% reduction in 
mortality over the 3 years of the study.68
ICS–LABA combination therapy
Several studies have examined the therapeutic strategy of 
combination therapy. Four of these have been comparative 
placebo-controlled studies with SFC104,111 or formoterol-
budesonide.112,113 The formoterolbudesonide studies all 
excluded any ‘cardiovascular disorder that may have put 
patients at risk’ but the SFC studies did not exclude such 
patients. All of these studies recruited patients with moderate 
to severe COPD and all found similar decrements in 
exacerbation rates of about 25% compared to placebo and a 
modest improvement in quality of life relative to placebo. Only 
the TORCH study was designed with mortality as the primary 
outcome measure. However the primary analysis found no 
statistically significant difference in mortality between the 
SFC and placebo arms (p = 0.052) perhaps because as the 
authors suggested, an interim analysis was undertaken to look 
at mortality indices for which the sample size calculation did 
not allow. The trends in the survival curves of the two arms are 
certainly suggestive of an effect on mortality that is supported 
by the prespecified secondary analyses.104
Comparison of ICS with ICS–LABA preparations 
was undertaken in all four studies. The exacerbation rate 
with ICS–LABA was no different from ICS in all the four 
studies. However, in two studies, ICS–LABA was better 
than ICS alone in total SGRQ score104,111 but only in the 
activities and impacts subscales of the SGRQ113 with no 
difference in the other study.112 In the TORCH study, 
mortality was significantly better in the SFC arm compared 
to the fluticasone arm (p = 0.028) but not compared to the 
salmeterol arm (p = 0.58). Thus it appears that addition of the 
LABA to fluticasone significantly modified the therapeutic 
effects of the ICS.104 However, as stated above, when a 
factorial analysis of the TORCH data is performed, it appears 
that this may all be due to the LABA.68International Journal of COPD 2009:4 211
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Long-acting antimuscarinic agents
Interest in long-acting antimuscarinic antagonists (LAMAs) 
followed from the ERS and ATS recommendations for 
the use of the short-acting anticholinergic, ipratropium in 
COPD.113,121 The pathophysiologic basis for anticholinergic 
agents in COPD is the increased vagal tone thought to exist 
in the airways of COPD patients122,123 and this work has 
been supported by more recent work on the physiology 
of tiotropium activity on the airways,124–130 Three major 
studies, conducted within the last 6 years have established 
the role of the LAMA, tiotropium, in stable COPD.131–133 The 
Casaburi study was a 12-month placebo-controlled study of 
921 patients with FEV1 of 39% predicted in 50 centers and the 
Niewoehner study was a 6-month study of 1829 patients with 
FEV1 36% in 26 Veterans Medical Centers. Both the Casaburi 
and Niewoehner studies showed about a 14% decrease in 
patients with exacerbations, a 15%–20% decrease in annual 
exacerbation rates and in the case of the Casaburi study a 
47% decrease in hospitalization rates for exacerbations. In 
addition, the Casaburi study found that 49% of patients on 
tiotropium had more than a 4-unit increase in SGRQ total 
score; these results were supported by the comparative study 
of Donohue et al.134
None of the above studies was powered to detect 
differences in mortality. However mortality was a secondary 
outcome measure of the UPLIFT study (Table 1).135 Mortality 
for all patients in this study was determined on an intent to 
treat basis and was known at 45 months in 98% subjects 
(tiotropium) and 97% (placebo).136 At the predetermined 
endpoint of 4 years and 30 days there was no significant 
difference between the two arms of the study (odds ratio, 0.89; 
p = 0.09); however after unblinding, analysis showed that 
there was a decreased risk of death in the tiotropium arm at 
4 years (odds ratio 0.87; 95% CI 0.76–0.99).136
LAMA vs ICS–LABA
There are two studies which allow us to compare these 
drugs: the INSPIRE and OPTIMAL studies. The largest 
comparative study so far published is the 2-year INSPIRE 
study47,51 which involved 1323 patients randomized to SFC 
or tiotropium with FEV1 of 39%. The study showed the rate 
of treated exacerbations, the primary outcome measure, was 
about 1.30 in both arms and the rate of all exacerbations 
whether treated or not was about 3.0 in both arms. However 
there was an unexpected 29% greater risk of dropout from 
the study in the tiotropium arm. The study found that at the 
end of 2 years, there was a 2.1 unit (p = 0.038) improvement 
in quality of life as measured by the SGRQ in the SFC arm 
compared to the tiotropium arm but this may have been due 
to a healthy survivor effect, as patients whose wellbeing 
was deteriorating more rapidly withdrew sooner, more so in 
the tiotropium arm.47 There was also a 3% mortality rate on 
treatment in the SFC arm compared to 6% in the tiotropium 
arm (p = 0.008), which was also unexpected. There is no clear 
explanation for this difference which the authors attributed 
to an improvement in survival due to SFC consistent with 
the results of the TORCH study.
The INSPIRE study also detected a difference in 
exacerbation phenotype in that antibiotic-treated exacerbations 
were more frequent in the SFC arm (p = 0.028) but systemic 
corticosteroid-treated exacerbations were more frequent 
in the tiotropium arm (p = 0.039) and there was a trend 
toward fewer hospitalizations for COPD exacerbations 
in the SFC arm (13% vs 16%; p = 0.085).47 These two 
results taken together are suggestive of a trend toward less 
severe exacerbations in the SFC arm. However this must be 
balanced against an increased risk of pneumonia in the SFC 
patients (8% vs 4%). One hypothesis that may explain this 
observation is that in some way SFC decreased the severity 
of exacerbations, making it less likely that they would be 
treated.
In the OPTIMAL Study, tiotropium–placebo (N = 156) 
was compared to tiotropium–salmeterol (N = 148) or a 
triple therapy combination with tiotropium SFC (N = 145) 
over 1 year; all comparisons were between the placebo 
and nonplacebo arms.137 The primary analysis showed 
no differences in annual exacerbation rates between the 
three arms of the study though the rate was lowest in the 
tiotropium SFC arm. However, there was a significant 
decrease in exacerbations requiring hospitalization in the 
SFC containing arm (rate ratio 0.53; 95% CI 0.33–086), 
thus suggesting that addition of SFC reduced the severity of 
exacerbations which was supported by a significant reduction 
in all-cause hospitalization. There were also differences in 
favor of tiotropium SFC in HRQoL. Thus it appears that 
addition of SFC to tiotropium decreases health burden in 
COPD. There was no mortality difference on treatment 
between the two arms. The results of the OPTIMAL study 
have been supported by two recent studies of triple therapy 
which showed physiological benefit for the triple therapy 
combination.138,139 The UPLIFT study design allowed use of 
other inhaled therapy in both arms and 74% of subjects in this 
study were on ICS, and thus the UPLIFT study may be seen 
to extend the results of the OPTIMAL study in that UPLIFT 
showed that there was a 14% decrease in exacerbation rates 
on top of usual care (p  0.001) compared to placebo.136International Journal of COPD 2009:4 212
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The data from the UPLIFT study taken together with those 
of the OPTIMAL study are suggestive of a superior effect for 
the combination ICS–LABA–LAMA. An economic analysis 
of this option showed that while the health burden was less 
(because of better quality of life and fewer hospitalizations) 
this was achieved at considerable economic cost.140 Thus the 
option of ICS–LABA–LAMA requires further study.
Macrolide use in COPD
Effects of antibiotics in non-COPD 
obstructive lung diseases
The evidence that antibiotics, specifically macrolides, may be 
useful in COPD comes from studies in two other obstructive 
lung diseases. Studies in diffuse panbronchiolitis, a disease 
that is prevalent in Far Eastern populations, showed that 
erythromycin improves survival and symptoms.141–143 This 
stimulated work in cystic fibrosis a disease common in 
Caucasian populations where azithromycin has been shown to 
decrease cystic fibrosis exacerbations and symptoms.144–147
Should macrolides have an effect on COPD? The 
effectiveness of macrolides in these two diseases led to 
investigations in the far more globally prevalent COPD. An initial 
open label study showed a decrease in COPD exacerbations in 
Japanese subjects.148 These results have been strongly supported 
by the recently concluded ELECT study.149
The eLeCT Study
This randomized, placebo-controlled trial of erythromycin 
250 mg twice daily in 109 moderate to severe stable COPD 
patients already on optimal therapy, was conducted in the 
long-running London COPD Cohort over 1 year. Patients were 
excluded if in the opinion of the investigator they had unstable 
cardiovascular status, for example congestive cardiac failure, 
cardiac arrhythmias or prolonged corrected QT duration on the 
electrocardiograph. The primary analysis showed a 35% fall 
in the exacerbation rate in the interventional arm. Secondary 
analyses showed that the median time to the first exacerbation 
was 271 days vs 89 days in the placebo arm (p = 0.020). 
Exacerbations in the erythromycin arm had a median duration 
of 9 days vs 13 days in the placebo arm (p = 0.001). The 
investigators were unable to find any differences in serum 
C reactive protein or serum interleukin (IL6) between the 
two arms of the study. There were no differences in sputum 
markers (IL6, IL8, myeloperoxidase) between the two arms of 
the study, though this analysis was limited by the variability 
in spontaneous sputum production by patients in the study. 
There was one death only in the study: in the placebo arm. 
Safety analyses showed no trend toward more adverse events 
or macrolide resistance in the interventional arm over the 1 
year of study. Thus the macrolide erythromycin would appear 
to be well tolerated over 1 year in moderate to severe COPD 
patients and it reduces COPD exacerbation duration and rates, 
but the mechanism by which this is achieved is not clear.
Phosphodiesterase inhibitors
These are a class of nonsteroidal anti-inflammatory drugs that 
may be useful in COPD. Prior comparative studies with LABAs 
have not shown much promise150 but in a recent RCT involving 
110 COPD patients, the theophylline arm was associated with a 
lower frequency of COPD exacerbations, fewer days of COPD 
exacerbations and improved quality of life indices. Mortality 
data were not available for this study.151 The only large 
controlled study of the newer phosphodiesterase inhibitors 
is a 647-patient study of cilomilast, which has reported a 
39% reduction in exacerbation rates and an improvement 
in health status using the SGRQ by 4.1 units compared with 
placebo (p = 0.001).152 Inhibition of another receptor subtype 
(PDE7A) has also been suggested to lead to decreased inflam-
mation in COPD.153 Our understanding of prevention of COPD 
exacerbations using this class of drugs is evolving.
Immunostimulatory agents  
and vaccines
vaccines
In a study of elderly patients with chronic lung disease, Nichol 
et al found that influenza vaccination is associated with 
significant health benefits with fewer outpatient visits, fewer 
hospitalizations and a reduced mortality.154 In a Cochrane 
database review of four studies in COPD, Granger et al found 
little effect for the injectable antipneumococcal vaccines,155 
but Alfageme et al studied the 23 serotype pneumococcal 
polysaccharide vaccine in 596 COPD patients and showed 
that the pneumococcal vaccine was effective in the prevention 
of community acquired pneumonia compared to placebo in 
patients less than 65 years old or those with severe airflow 
obstruction (FEV1  40%) without a difference in mortal-
ity.156 Larger studies are required to examine the effects of 
the vaccine in those over 65 with COPD.
Immunostimulatory agents
There are inconsistent reports of the effectiveness of these 
agents in COPD. One study, the detoxified oral immunoactive 
bacterial extract, OM85, was associated with fewer COPD 
exacerbations and hospital admissions157 but a systematic 
review of 13 trials involving 2066 patients found no consistent 
evidence of a benefit, though the drug is currently in use.158International Journal of COPD 2009:4 213
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Mucolytic agents
A Cochrane database review of 26 trials involving 7335 
patients with COPD has shown that mucolytic agents are 
associated with a 20% reduction in exacerbation rates 
and decreased days of disability.159 However there were 
contrasting effects observed in two RCTs. In the BRON-
CHUS study of 523 patients from 10 European countries, 
nacetylcysteine had no effect on exacerbation rates but 
subgroup analyses showed a small decrease in patients 
who were not on regular inhaled steroids.160 The PEACE 
study of carbocysteine in 709 Chinese COPD patients 
found a 25% reduction in exacerbation rates and improved 
quality of life in the interventional arm.161 The reasons for 
these differences may depend on the differing populations 
studied.161 The studies were both of similar sizes and had 
similar exclusion criteria. However the BRONCHUS study 
recruited less severe patients with FEV1% predicted 57% 
vs 43% in the PEACE study. Also in the BRONCHUS 
study 70% of patients were on ICS vs 16.7% in the PEACE 
study. The authors in the PEACE study speculated that 
the difference in the two studies arose because of the dif-
fering pharmacologic properties of carbocysteine which 
may in part depend on inhibition of viral adherence to the 
airway.161 The authors further speculated that some of the 
differences between the two study results may also be due 
to pharmcogenetic differences between Caucasian and 
Chinese populations as well as the lesser use of ICS in the 
Chinese population.
Nonpharmacologic therapies pulmonary 
rehabilitation and exercise
A 1-year RCT of 200 disabled COPD patients with FEV1 
39% showed that there were no differences in number of 
hospitalizations following a 6-week rehabilitation program 
but fewer days in hospital and fewer primary care home 
visits in the rehabilitation group.162 This indicates that 
pulmonary rehabilitation may affect severity of exacerbations 
but not the rate which has been supported by a study of 
housebound COPD patients,163 though another study with 
repeated yearly rehabilitation programs found a decreased 
rate of hospitalization and exacerbations.164 There were 
also significant improvements in quality of life scores that 
remained significant at 1 year after the program162,165 and 
fewer deaths in the interventional group (3 vs 9).162
The results of the Griffiths study differ somewhat in 
conclusion from those of a systematic review of 6 random 
ized controlled trials of pulmonary rehabilitation involving 
230 patients (but not including the Griffiths Study) where 
there was a decreased risk of readmission to hospital (pooled 
relative risk 0.26 [0.12–0.54]) and decreased mortality 
(RR 0.45 [0.22–0.91]).166 A Cochrane review of 31 RCTs of 
pulmonary rehabilitation found significant improvements in 
quality of life using the CRQ and in two of the three domains 
of the SGRQ.212 However effects of pulmonary rehabilitation 
may depend of the initial level of dyspnea82 and repeated 
pulmonary rehabilitation programs may lose some effective-
ness, though they are associated with preserved quality of 
life indices despite physiologic deterioration.167 Pulmonary 
rehabilitation is now an accepted intervention in COPD 
regardless of age or debility82,163,168 with important benefits 
for patients on outcomes such as the exercise capacity and 
quality of life but there is no consensus on its effects on COPD 
exacerbations and there is weak evidence for at least a short 
term effect on mortality.
GarciaAymerich et al169 have also shown in a 1-year study 
that patients with high levels of usual physical activity were 
at reduced risk of readmission to hospital. These results have 
been supported by analysis of data from the Copenhagen 
City Heart Study.170 In this study patients were classified by 
self-reported physical activity and those who reported some 
degree of physical activity had a lower risks of hospitalization 
and all-cause mortality (hazard ratio 0.76, 95% CI 0.65–0.90) 
and a trend toward decreased respiratory mortality.170
Noninvasive ventilation
The use of noninvasive ventilation (NIV) in acute hypercapnic 
respiratory failure is an accepted intervention.171 However 
the evidence for its use in stable COPD is controversial. 
In one study of a highly selective group of 13 stable COPD 
patients with frequent admissions for decompensated type 
two respiratory failure and who tolerated the ventilator, 
there were significant falls in inpatient length of stay and 
number of hospital admissions compared to a period prior 
to intervention.172 In a larger 2-year RCT of NIV with and 
without long-term oxygen therapy involving 90 patients, 
there was an improvement in quality of life in the NIV 
arm but no difference in survival or exacerbations leading 
to hospitalization.173 However a recent prospective 
observational study of 99 patients with, and 41 without 
NIV, showed that survival rates were significantly higher 
in patients with NIV compared to those without this therapy 
(hazard ratio; 0.380; 95% CI 0.138–0.606) and this difference 
persisted after adjustment for baseline differences.174 
Interestingly there were beneficial effects in those with 
high base excess, low pH, low FEV1 or low hemoglobin 
or excessive hyperinflation.174 In a small Chinese study of International Journal of COPD 2009:4 214
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40 patients with hypercapnic respiratory failure, randomized 
with and without NIV, there was a decrease in exacerbations 
by 3.9/year (p  0.01) and a trend toward improved mortality 
in the interventional group.175 Thus, the observation made 
6 years ago is still valid; there is a need for well-designed 
controlled studies to evaluate the effects of NIV on survival, 
quality of life and exacerbations.176
Long-term oxygen therapy (LTOT)
The role of LTOT was established about 28 year ago by 
two major studies.177,178 Guidelines for oxygen use have 
been generally agreed to by several consensus panels.179 
LTOT improves mortality in COPD patients with respiratory 
failure but there appears to be no effect in the less severe 
patients.177,178,180 There are also positive effects on quality 
of life73,181 but no proven effect on COPD exacerbations. 
The relationship with improved quality of life may lead 
to speculation that this may in part be due to decreased 
exacerbation rates but most of these studies did not include 
exacerbation rates as an outcome measure and the MRC study 
found no relationship with rates of hospitalization.178
Safety and tolerability
The sections above have highlighted the many therapies that 
have demonstrated efficacy in reducing exacerbation rate, and 
thereby impacting favorably on health status and mortality. 
In this section we will review data on safety and tolerability 
for the more commonly used pharmacologic interventions 
where there have been several consistent results. However, 
the key point remains as to whether such interventions are 
safe, and tolerable. This is the subject of the following two 
sections. Only then can we achieve the ‘Holy Grail’ of phar-
macotherapy in providing the right drug, at the right dose, to 
the right patient at the right time.
It is important to make the distinction, having assumed 
efficacy, between safety and tolerability. A tolerable drug 
may be unsafe, and likewise a safe drug may be intolerable. 
There are complex interactions between efficacy, tolerability 
and safety in individual patients (Figure 1). The ideal 
preparation is efficacious, safe and tolerable.
Useful tolerability data may be obtained from those few 
key large trials that have now been performed in patients with 
COPD, and meta-analyses of smaller studies. These safety 
and tolerability data are summarized in Table 1.
Tolerability/patient preference
The TORCH trial104 showed that even in highly motivated 
and monitored clinical trial environments 34% of patients 
had discontinued a LABA–ICS combination at 3 years, and 
this rate (and those of the individual components) was signifi-
cantly better than placebo. Withdrawal from the combination 
was significantly lower than that with the components alone, 
suggesting a relationship between efficacy and tolerability. 
This withdrawal rate matched that for the LABA–ICS combi-
nation in the INSPIRE trial,47 a head-to-head comparison with 
the long-acting anticholinergic drug tiotropium bromide and 
in which tiotropium was associated with a 42% withdrawal 
rate. Interpretation of the data from the INSPIRE study 
has not been supported by that of the UPLIFT study which 
showed a lower dropout rate in the tiotropium arm, though 
the designs of these two studies were different in that the 
INSPIRE study was largely a comparison of two arms each 
with monotherapy but the UPLIFT study allowed polytherapy 
in each arm.136 In the OPTIMAL Study137 premature discon-
tinuation rates were as follows: 47% (tiotropium–placebo), 
43% (tiotropium–salmeterol) and 26% (tiotropium–SFC) 
(p  0.001). Discontinuation was due to a perceived lack 
of medication efficacy or physician directed and due to a 
perceived deterioration in health status. Of these early with-
drawals the proportion receiving an open label ICS–LABA 
combination were 74%, 70% and 54%, respectively.137 These 
results appear to support those of the INSPIRE study on 
withdrawals and may indicate a trend in patient preference. 
However compliance/satisfaction within a trial may not reflect 
behavior in clinical practice. One retrospective study in the 
Netherlands found that about 37% of new users of tiotropium 
continued treatment for 1 year, compared with 14% for 
ipratropium, 13% for LABA, and 17% for ICS–LABA but 
compliance was increased in all groups after hospitalization.182 
These results are supported by those of a Canadian study 
of inhaled steroids between 1990 and 1995.183 Differential 
Tolerability
Safety Efficacy
Safe,
Tolerable
Efficacious,
Figure 1 The interaction of safety, tolerability and efficacy.International Journal of COPD 2009:4 215
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withdrawal rates also complicate interpretation of data from 
trials, as a greater number of more severe patients are likely 
to withdraw from the placebo arm leaving the placebo arm 
containing a higher proportion of milder patients, potentially 
biasing against the beneficial effects of an intervention but 
also making an intent to treat analysis difficult (Table 2).
Combining the tolerability/patient preference results 
of the three long term studies discussed above, it would 
appear that the most tolerable combination is ICS–LABA–
LAMA but it is too early to draw a definitive conclusion at 
this stage.
The smaller studies involving the mucolytic agents 
or erythromycin found no differences in withdrawal rates 
compared to placebo.149,160,161
Safety
The TORCH data were the first to suggest that ICS-containing 
regimens may be associated with an increased risk of a com-
plication termed ‘pneumonia,’ but it should be noted that 
radiological confirmation of pneumonia was not required 
and so these pneumonia episodes may not be more precisely 
characterized.104 The results are however supported by the 
INSPIRE data which reported pneumonias in 8% in the SFC 
arm and 4% in the tiotropium arm. Most of these pneumonias 
required hospitalization and there were three deaths due to 
pneumonia in INSPIRE, all in the SFC arm. However in 
spite of this, INSPIRE still reported a mortality reduction on 
treatment in favor of SFC.47
Reassuringly, TORCH did not demonstrate an increase in 
the development of cataracts with ICS-containing regimes, 
or a reduction in bone mineral density or increase in 
fracture risk. Similarly, LABA-containing regimes were not 
associated with excess cardiovascular events.104,116,184,185 ICS 
was associated with an increased incidence of oropharyngeal 
candidiasis.
The  safety  of  tiotropium  has  been  reported  in 
a meta-analysis of nine randomized trials including data 
from 8002 patients.186 The data did not support an effect of 
tiotropium on all-cause (or pulmonary) mortality (OR 0.96, 
95% CI 0.63–1.47). Only dry mouth was more common than 
with placebo, but when compared with other comparator 
drugs such as ipratropium or salmeterol there was an 
increased risk of urinary tract infection and, with further 
allowance for heterogeneity, an observed increased risk 
of arrythmias (OR 2.33, 95% CI 1.11–4.88). All three of 
the major tiotropium studies131–133 excluded patients who 
had a recent myocardial infarction, heart failure or cardiac 
arrhythmias. Thus the publication of a recent meta-analysis 
T
a
b
l
e
 
2
 
S
a
f
e
t
y
 
a
n
d
 
t
o
l
e
r
a
b
i
l
i
t
y
I
n
t
e
r
v
e
n
t
i
o
n
S
a
f
e
t
y
T
o
l
e
r
a
b
i
l
i
t
y
R
e
m
a
r
k
s
R
e
f
e
r
e
n
c
e
I
C
S
 
v
s
 
L
A
B
A
 
v
s
 
B
o
t
h
 
v
s
 
P
l
a
c
e
b
o
S
i
g
n
i
fi
c
a
n
t
 
i
n
c
r
e
a
s
e
 
i
n
 
r
i
s
k
 
o
f
 
‘
p
n
e
u
m
o
n
i
a
’
 
i
n
 
p
a
t
i
e
n
t
s
 
t
a
k
i
n
g
 
a
n
 
I
C
S
 
c
o
n
t
a
i
n
i
n
g
 
p
r
e
p
a
r
a
t
i
o
n
 
(
1
9
.
6
%
 
b
o
t
h
,
 
1
8
.
3
%
 
I
C
S
 
v
s
 
1
2
.
3
%
 
p
l
a
c
e
b
o
 
 
p
 

 
0
.
0
0
1
 
o
r
 
1
3
.
3
%
 
L
A
B
A
)
.
 
I
C
S
 
a
l
s
o
 
a
s
s
o
c
i
a
t
e
d
 
w
i
t
h
 
o
r
o
p
h
a
r
y
n
g
e
a
l
 
c
a
n
d
i
d
i
a
s
i
s
.
 
N
o
 
a
p
p
a
r
e
n
t
 
e
f
f
e
c
t
 
o
f
 
I
C
S
 
o
n
 
B
M
D
 
o
r
 
f
r
a
c
t
u
r
e
 
r
i
s
k
,
 
o
r
 
o
f
 
L
A
B
A
 
o
n
 
c
a
r
d
i
o
v
a
s
c
u
l
a
r
 
e
v
e
n
t
s
.
P
l
a
c
e
b
o
:
 
4
4
%
 
w
i
t
h
d
r
a
w
a
l
.
 
r
r
 
i
n
 
f
o
l
l
o
w
i
n
g
 
g
r
o
u
p
s
 
c
o
m
p
a
r
e
d
 
t
o
 
p
l
a
c
e
b
o
 
0
.
6
9
 
(
0
.
6
2
–
0
.
7
8
,
 
 
p
 

 
0
.
0
0
1
)
 
f
o
r
 
b
o
t
h
,
 
0
.
7
8
 
(
0
.
7
0
–
0
.
8
6
,
 
p
 

 
0
.
0
0
1
)
 
f
o
r
 
L
A
B
A
 
a
n
d
 
0
.
8
1
 
(
0
.
7
2
–
0
.
9
0
,
 
p
 

 
0
.
0
0
1
)
 
f
o
r
 
I
C
S
.
3
 
y
e
a
r
 
s
t
u
d
y
,
 
6
1
8
4
 
 
i
n
 
s
a
f
e
t
y
 
a
n
a
l
y
s
i
s
T
O
r
C
H
I
C
S
 
+
 
L
A
B
A
 
v
s
 
T
i
o
t
r
o
p
i
u
m
L
o
w
e
r
 
m
o
r
t
a
l
i
t
y
 
i
n
 
S
F
C
 
v
s
 
T
I
O
 
(
3
%
 
v
s
 
6
%
,
 
p
 
=
 
0
.
0
3
2
)
 
w
h
i
c
h
 
m
a
y
 
r
e
l
a
t
e
 
t
o
 
m
o
r
e
 
c
a
r
d
i
o
v
a
s
c
u
l
a
r
 
e
v
e
n
t
s
 
i
n
 
T
I
O
.
 
I
n
c
r
e
a
s
e
d
 
p
n
e
u
m
o
n
i
a
 
i
n
 
S
F
C
 
v
s
 
T
I
O
 
(
8
%
 
v
s
 
4
%
)
.
I
C
S
 
+
 
L
A
B
A
 
w
i
t
h
d
r
a
w
a
l
 
3
5
%
 
v
s
 
t
i
o
t
r
o
p
i
u
m
 
4
2
%
 
p
 
=
 
0
.
0
0
5
.
2
 
y
e
a
r
 
s
t
u
d
y
,
 
1
3
2
3
 
p
a
t
i
e
n
t
s
 
r
a
n
d
o
m
i
z
e
d
I
N
S
P
I
r
e
T
i
o
t
r
o
p
i
u
m
A
l
l
 
c
a
u
s
e
 
m
o
r
t
a
l
i
t
y
 
v
s
 
p
l
a
c
e
b
o
:
 
O
r
 
0
.
9
6
,
 
9
5
%
 
 
C
I
 
0
.
6
3
–
1
.
4
7
.
 
C
o
m
p
a
r
e
d
 
w
i
t
h
 
p
l
a
c
e
b
o
 
g
r
e
a
t
e
r
 
d
r
y
 
m
o
u
t
h
 
b
u
t
 
n
o
t
 
c
o
n
s
t
i
p
a
t
i
o
n
,
 
u
r
i
n
a
r
y
 
r
e
t
e
n
t
i
o
n
 
o
r
 
v
a
s
c
u
l
a
r
/
a
r
r
h
y
t
h
m
i
a
s
.
8
0
0
2
 
p
a
t
i
e
n
t
s
B
a
r
r
1
8
6
 
M
e
t
a
-
a
n
a
l
y
s
i
s
I
C
S
I
n
c
r
e
a
s
e
d
 
o
r
o
p
h
a
r
y
n
g
e
a
l
 
c
a
n
d
i
d
i
a
s
i
s
 
r
r
 
2
.
1
,
 
9
5
%
 
C
I
 
1
.
5
3
–
3
.
1
0
;
 
b
r
u
i
s
i
n
g
 
r
r
 
=
 
2
.
1
;
 
9
5
%
 
C
I
 
1
.
6
–
2
.
8
 
a
n
d
 
l
o
w
e
r
 
m
e
a
n
 
c
o
r
t
i
s
o
l
.
 
N
o
 
m
o
r
t
a
l
i
t
y
 
e
f
f
e
c
t
.
 
e
f
f
e
c
t
 
o
n
 
B
M
D
 
v
a
r
i
a
b
l
e
.
 
N
o
 
d
i
f
f
e
r
e
n
c
e
s
 
i
n
 
c
a
t
a
-
r
a
c
t
 
o
r
 
f
r
a
c
t
u
r
e
 
(
b
u
t
 
s
h
o
r
t
 
f
o
l
l
o
w
 
u
p
)
.
9
 
t
r
i
a
l
s
,
 
3
9
7
6
 
p
a
t
i
e
n
t
s
A
l
s
a
e
e
d
i
1
8
8
 
S
y
s
t
e
m
a
t
i
c
 
a
n
a
l
y
s
i
s
L
A
B
A
N
o
 
i
n
c
r
e
a
s
e
d
 
a
d
v
e
r
s
e
 
e
v
e
n
t
s
,
 
c
l
i
n
i
c
a
l
,
 
l
a
b
o
r
a
t
o
r
y
 
o
r
 
e
C
G
,
 
c
o
m
p
a
r
e
d
 
t
o
 
p
l
a
c
e
b
o
 
o
v
e
r
 
1
2
 
w
e
e
k
s
.
1
3
5
 
s
a
l
m
e
t
e
r
o
l
,
 
1
4
3
 
p
l
a
c
e
b
o
.
M
a
h
l
e
r
1
1
6
A
b
b
r
e
v
i
a
t
i
o
n
s
:
 
I
C
S
,
 
i
n
h
a
l
e
d
 
c
o
r
t
i
c
o
s
t
e
r
o
i
d
s
;
 
L
A
B
A
,
 
l
o
n
g
-
a
c
t
i
n
g
 
β
2
-
a
g
o
n
i
s
t
s
;
 
B
M
D
,
 
b
o
n
e
 
m
i
n
e
r
a
l
 
d
e
n
s
i
t
y
;
 
R
R
,
 
r
e
l
a
t
i
v
e
 
r
i
s
k
;
 
S
F
C
,
 
s
a
l
m
e
t
e
r
o
l
–
fl
u
t
i
c
a
s
o
n
e
;
 
T
I
O
,
 
t
i
o
t
r
o
p
i
u
m
;
 
O
R
,
 
o
d
d
s
 
r
a
t
i
o
;
 
C
I
,
 
c
o
n
fi
d
e
n
c
e
 
i
n
t
e
r
v
a
l
.International Journal of COPD 2009:4 216
Seemungal et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
of seventeen trials involving ipratropium or tiotropium 
which showed an increased risk of cardiac complications 
in COPD patients met with some consternation187 and the 
need for a long term prospective study was felt necessary 
to answer the question of safety definitively. The UPLIFT 
study (Table 1) was recently published and has shown a 
decreased risk of cardiac complications in the tiotropium 
arm vs placebo arm at 4 years, though it is to be noted 
that patients in both arms of the study were also on other 
inhaled therapies.136
A systematic review of RCTs of ICS in COPD also showed 
no overall mortality effect (RR 0.84, 95% CI 0.60–1.18)188 
and significant increases in oropharyngeal candidiasis and 
bruising. No increased risk of fractures or cataracts were 
observed in the short follow-up periods, and effects on bone 
mineral density were variable. Similarly, effects on serum 
cortisol levels varied. This must be interpreted on the back-
ground of larger studies demonstrating effects of ICS on 
cataracts,189,190 osteoporosis191 and adrenal suppression.192
The side effects of LABA are well described. However, the 
particular concern in COPD has always been of cardiovascular 
risk, particularly with regard to tachyarrhythmias, following 
stimulation of cardiac β-adrenoceptors. Small studies of less 
than 1 year’s duration have assured us of the cardiovascular 
safety of salmeterol (50 µg twice daily) and formoterol in 
COPD.115,116,150,184,193–195 The question was also addressed in 
a meta-analysis of 1410 patients from 7 trials up to 1 year in 
duration using the LABA salmeterol (50 µg BD) in comparison 
to 1443 on placebo.184 The relative risk for cardiovascular 
adverse events was 1.03 (95% CI 0.81.3; p = 0.838). Unlike 
other drug classes, meta-analyses of efficacy of LABA in 
COPD have not generally reported safety and tolerability. 
These results have been confirmed in the 1-year prospective 
studies for both salmeterol111 and formoterol112,113 and for 
salmeterol over 4 years.104
With regard to the newer drugs used in COPD no 
significant cardiovascular side effects were reported for 
erythromycin149 or cilomilast152 but cilomilast was associ-
ated with a significantly greater incidence of gastrointestinal 
side effects affecting daily life (17% vs 8% placebo). No 
safety issues have been reported in long-term studies of the 
mucolytic agents.160,161
Patient-focused perspectives
Metered dose inhalers
Pressurized metered dose inhalers (pMDIs), though easy 
to use, are critically dependent on inhalational technique to 
achieve acceptable lung deposition, which can be improved 
through use of add-on valve holding chambers (spacers), 
but these are seldom used in the clinical practice possibly 
because they are cumbersome.196 Inclusion of a dose counter 
may significantly improve patient satisfaction with metered 
dose inhalers.196
Breath-actuated devices
These include the dry powder inhalers (DPIs). They are 
environmentally safe, easily carried by the patient and do 
not incur patient-centered difficulty with hand inhalation 
coordination as may occur with pMDI usage. However, in a 
systematic review of COPD and asthma, Lavorini et al found 
that there were several problems with their use: (a) failure to 
exhale before actuation, (b) failure to breathhold after inha-
lation, (c) incorrect positioning of the inhaler, (d) incorrect 
rotation sequence, and (e) failure to execute a forceful and 
deep inhalation.197 In a small study of elderly COPD patients 
with matched controls, Janssens et al found that 30% of 
COPD patients did not achieve the recommended flow rate198 
and these results are supported by other studies.199,200 Thus 
significant training may be required for patents to achieve 
therapeutic benefit form their inhalers.
Nebulizers
Nebulizers are relatively difficult and time consuming to 
use and need to be maintained. However their use requires 
less coordination compared to inhalers and one study of 82 
patients in the UK found that patients felt overwhelmingly 
that the benefits of using a nebulizer outweighed potential 
disadvantages.201
Thus from a patient-centered perspective, the choice of 
an inhaler device is a key component of COPD therapy and 
this requires more attention from physicians than perhaps 
we are aware of.
Disease management programs
The major features of these programs are (1) adherence to 
guidelines (2) use of a nurse with special training in that disease 
and (3) central coordination with patientcenteredness.202 
During the Dutch Quality of Care Through Patients Eyes 
(QUOTE) Study of patients with asthma and COPD, the 
proportion of patients reporting good accessibility improved 
from 57% to 73% and good coordination of care from 63% 
to 77% (p  0.05 in both cases).203,204 Patient satisfaction 
improved as the study progressed.203 Thus coordination of 
care and accessibility to health care personnel are two key 
features of patient satisfaction. An intensive disease-specific 
self-management programme carried out in Canada has International Journal of COPD 2009:4 217
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been shown to reduce hospital readmission rate205 or deaths 
following hospitalization but not readmissions,206 though a 
systematic review of nurse interventions failed to show a 
consistent effect on hospitalization.207 Another randomized 
study of organized care was based on a so-called chronic 
platform ‘chronic platform,’ which was a web-based 
application that facilitated phone calls to the case manager, as 
well as record keeping via phone calls, home visits or home 
video conferencing, and which again emphasized improved 
communication and nurse practitioner importance.208 Patient 
satisfaction was not an outcome measure in this study but 
patients in the interventional arm had significantly less read-
missions to hospital,208 similar to those of a Spanish study 
of integrated care.209
The results of the above two European and Canadian 
studies are different from those of a Dutch study which 
found no effect of a self-management program in 248 
COPD patients.210 However the Dutch study involved less 
severe patients who had not been admitted to hospital. Thus 
self management programs are associated with significant 
improvements in several processes211 and may be more useful 
in the more severe patients who have had at least one hospi-
talization. Finally we may observe that it appears to be too 
early to determine whether self-management programs will 
have an effect on mortality but their fairly uniform effect on 
exacerbation severity as assessed by hospital admission rates 
is certainly consistent with this hypothesis and supported by 
the results of the SolerCataluña study.66
Conclusions
Amongst the common chronic diseases, the term COPD is 
relatively new but is extremely prevalent in Western society 
and its incidence is rising in the developing world. COPD is 
generally underdiagnosed and undertreated. Exacerbations 
of COPD, about 50% of which are reported to physicians, 
lead to a deterioration in the quality of life and contribute 
significantly to disease burden. There is heterogeneity in the 
definition of COPD exacerbations, and for interventional 
studies to decrease exacerbation rates in a reproducible 
manner we must have amore precise definition of a COPD 
exacerbation. So far an objective marker is lacking but current 
efforts may soon yield positive results.
Patient quality of life deteriorates with time. Most of 
the health burden of COPD occurs in the more severe disease 
and is due to hospitalization which is an outcome measure 
that can be modified. COPD severity, and frequent and more 
severe exacerbations are all related to an increased risk of 
mortality.
Most of these outcome measures can be modified 
by current therapeutic strategies. Most inhaled steroid 
medications evaluated in long-term studies have similar 
effects on quality of life but may appear to differ in 
their effects on COPD exacerbations. The combination 
ICS–LABA and the LAMA, tiotropium, are likely to decrease 
mortality but perhaps only when used over a period of several 
years. In addition to this, they both improve health status and 
exacerbation rates. In a single center study the macrolide, 
erythromycin, has been shown to decrease the rate of COPD 
exacerbations but effects on mortality and quality of life are 
unknown. The new phosphodiesterase inhibitor cilomilast 
has been shown to improve quality of life and exacerbation 
rates but has significant gastrointestinal side effects.
Nonpharmacologic strategies are also of importance 
in COPD. Pulmonary rehabilitation is indicated in all 
severities of COPD and improves quality of life; effects on 
exacerbation rate and mortality are unclear. An unquanti-
fied degree of regular physical activity is associated with 
decreased hospitalization and mortality and may even prevent 
or delay onset of COPD. Noninvasive ventilation is associ-
ated with improved quality of life but studies have been too 
small to provide strong evidence for an effect on mortality. 
Long-term oxygen therapy improves mortality but only in 
hypoxic COPD patients. Disease management programs have 
a more holistic approach with emphasis on patient centered-
ness and communication, and are associated with decreased 
hospitalization rates and improved quality of life, but so far 
there are no studies of mortality. Most of these interventions 
are well tolerated and their safety profile in long-term studies 
has been shown to be good.
In the past 30 years there have been marked improve-
ments in the treatment of COPD. We now have interventions 
that are well tolerated and safe and decrease exacerbation 
rates and improve quality of life. Comparative studies 
of the nonpharmacologic and pharmacologic approaches 
are lacking. We must concentrate more efforts on patient 
education. Recent studies using drug combinations have 
been unable to achieve more than a 25% fall in exacerbation 
rates and thus there may be a need for research into new 
modalities of treatment. Whether LABA or ICS reduce 
mortality is no longer of relevance, as it is clear that the 
combination ICS–LABA reduces exacerbation rates and 
improves quality of life and is thus more efficacious than the 
individual therapies. Future research will look at combining 
therapies with different mechanisms of treatment such as 
ICS–macrolides or LAMA–phosphodiesterase. The goal 
would be to decrease exacerbation/hospitalization rates by International Journal of COPD 2009:4 218
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more than 50% either singly or in combination with current 
modalities of treatment.
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